tiprankstipranks
Trending News
More News >
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (HK:1276)
:1276
Hong Kong Market
Advertisement

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Price & Analysis

Compare
1 Followers

1276 Stock Chart & Stats


Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H News

1276 FAQ

What was Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$52.50 and its highest was HK$87.80 in the past 12 months.
    What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap?
    Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap is HK$478.57B.
      When is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
      Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date is Oct 24, 2025 which is in 54 days.
        How were Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
        Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H released its earnings results on Aug 18, 2025. The company reported HK$0.435 earnings per share for the quarter, beating the consensus estimate of HK$0.343 by HK$0.092.
          Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H overvalued?
          According to Wall Street analysts Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pay dividends?
            Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H does not currently pay dividends.
            What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
            Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate is 0.39.
              How many shares outstanding does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H have?
              Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 258,197,600 shares outstanding.
                What happened to Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
                Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H reported an EPS of HK$0.435 in its last earnings report, beating expectations of HK$0.343. Following the earnings report the stock price went up 1.767%.
                  Which hedge fund is a major shareholder of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H?
                  Currently, no hedge funds are holding shares in HK:1276

                  Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Stock Smart Score

                  9
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Fundamentals

                  Return on Equity
                  14.44%
                  Trailing 12-Months
                  Asset Growth
                  33.09%
                  Trailing 12-Months

                  Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Earnings & Revenues

                  1276 Stock 12 Month Forecast

                  Average Price Target

                  HK$97.52
                  ▲(27.98% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"HK$52","135":"HK$135","72.75":"HK$72.8","93.5":"HK$93.5","114.25":"HK$114.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":134,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$134.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$97.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$78.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,72.75,93.5,114.25,135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.8,59.96923076923077,66.13846153846154,72.3076923076923,78.47692307692307,84.64615384615385,90.81538461538462,96.98461538461538,103.15384615384616,109.32307692307693,115.49230769230769,121.66153846153846,127.83076923076923,{"y":134,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.8,57.16307692307692,60.526153846153846,63.889230769230764,67.25230769230768,70.61538461538461,73.97846153846153,77.34153846153845,80.70461538461538,84.06769230769231,87.43076923076923,90.79384615384615,94.15692307692308,{"y":97.52,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.8,55.661538461538456,57.52307692307692,59.38461538461538,61.246153846153845,63.107692307692304,64.96923076923076,66.83076923076923,68.6923076923077,70.55384615384615,72.41538461538461,74.27692307692308,76.13846153846154,{"y":78,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.7,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":57.7,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.8,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  CSPC Pharmaceutical Group
                  Wuxi Biologics (Cayman)
                  WuXi AppTec Co., Ltd. Class H
                  Hansoh Pharmaceutical Group Company Limited
                  BeiGene Ltd

                  Ownership Overview

                  0.53%99.46%
                  Insiders
                  0.53%
                  Mutual Funds
                  ― Other Institutional Investors
                  99.46% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis